<code id='C5BAE8D46D'></code><style id='C5BAE8D46D'></style>
    • <acronym id='C5BAE8D46D'></acronym>
      <center id='C5BAE8D46D'><center id='C5BAE8D46D'><tfoot id='C5BAE8D46D'></tfoot></center><abbr id='C5BAE8D46D'><dir id='C5BAE8D46D'><tfoot id='C5BAE8D46D'></tfoot><noframes id='C5BAE8D46D'>

    • <optgroup id='C5BAE8D46D'><strike id='C5BAE8D46D'><sup id='C5BAE8D46D'></sup></strike><code id='C5BAE8D46D'></code></optgroup>
        1. <b id='C5BAE8D46D'><label id='C5BAE8D46D'><select id='C5BAE8D46D'><dt id='C5BAE8D46D'><span id='C5BAE8D46D'></span></dt></select></label></b><u id='C5BAE8D46D'></u>
          <i id='C5BAE8D46D'><strike id='C5BAE8D46D'><tt id='C5BAE8D46D'><pre id='C5BAE8D46D'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          comprehensive

          author:Wikipedia    - browse:597
          New Sanofi Genzyme president Bill Sibold is the first person without any ties to Henri Termeer (inset) to lead the company. Jonathan Wiggs/Globe staff

          CAMBRIDGE, Mass. — When drug giant Sanofi restructured its global business two years ago, its Genzyme division got a new name, Sanofi Genzyme, explicitly tying it to the French parent company. It also got new responsibilities and a larger “specialty care” portfolio covering everything from enzyme replacement to cancer and multiple sclerosis drugs.

          Last week, Sanofi Genzyme — still the largest Massachusetts biotech, with about 5,000 workers — also got a new president, Bill Sibold. He’s the first one without any ties to the old Genzyme, an independent company that pioneered the rare-disease business model and catalyzed the local life sciences boom before accepting Sanofi’s $20.1 billion takeover offer in 2011.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          hotspot